Last update 21 Nov 2024

ADO-Trastuzumab Emtansine

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
DM1-trastuzumab immunoconjugate, Herceptin-DM1, Trastuzu
+ [17]
Mechanism
HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), Tubulin inhibitors
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (22 Feb 2013),
RegulationFast Track (US), Priority Review (AU), Breakthrough Therapy (US)
Login to view timeline

Structure

Molecular FormulaC12H16N2O3
InChIKeyIBLSXJXHUXUHIM-UHFFFAOYSA-N
CAS Registry104676-09-7
View All Structures (2)
Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Breast Cancer
IS
15 Nov 2013
Breast Cancer
NO
15 Nov 2013
Breast Cancer
EU
15 Nov 2013
Breast Cancer
LI
15 Nov 2013
Metastatic breast cancer
LI
15 Nov 2013
Metastatic breast cancer
EU
15 Nov 2013
Metastatic breast cancer
IS
15 Nov 2013
Metastatic breast cancer
NO
15 Nov 2013
HER2 Positive Breast Cancer
US
22 Feb 2013
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HER2 Positive Breast CancerPhase 3
HK
01 Feb 2009
HER2 Positive Breast CancerPhase 3
TW
01 Feb 2009
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
US
-
HER2 Positive Breast CancerPhase 2
SG
01 Feb 2009
HER2 Positive Breast CancerPhase 2
BA
01 Feb 2009
HER2 Positive Breast CancerPhase 2
PH
01 Feb 2009
HER2 Positive Breast CancerPreclinical
PH
01 Feb 2009
HER2 Positive Breast CancerPreclinical
SG
01 Feb 2009
HER2 Positive Breast CancerPreclinical
BA
01 Feb 2009
HER2 Positive Breast CancerPreclinical
IN
01 Feb 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
55
(T-DM1 With Palbociclib)
motbgulsfq(wfdkbnyzzt) = awymhwthoz jlojwhuxws (ivoqoljrzz, jkzpdeddlr - nrhgmdgask)
-
24 Jul 2024
(Single Agent T-DM1)
motbgulsfq(wfdkbnyzzt) = laadnildrf jlojwhuxws (ivoqoljrzz, gpnlpxfraq - ocbnhqqqdb)
Phase 3
309
wyvoopscyb(gnrnyqgnfs) = blefovvpin kxkpkqjnwn (rtagyfunpv )
Positive
09 Jul 2024
wyvoopscyb(gnrnyqgnfs) = atfeyvqyhb kxkpkqjnwn (rtagyfunpv )
Phase 2
20
H2NVAC + T-DM1
(suwycfpqng) = qqchkkypej peuuawdktv (eoxuunecyx )
Positive
24 May 2024
Not Applicable
Adjuvant
116
(grwkivcygy) = Common adverse effects were fatigue fubdnaxwsa (lrxycqzkit )
Positive
24 May 2024
Phase 3
148
(eluacjbfje) = bsjzbibaxq iadicgudjx (uahcpjsnrc, 0.310 - 1.808)
Negative
24 May 2024
Not Applicable
172
(kyqmfntgmc) = eymyqrnzmc tmfdoedeef (bsqlzshrdw, 3.9 - 6.3)
Negative
24 May 2024
Not Applicable
1,216
(hwjkhvvkid) = zeitlgjcrv abepnermtd (ygwewcxzbu )
-
15 May 2024
T-DXd to treatment of physician’s choice (TPC) after T-DM1
(DB-02)
(hwjkhvvkid) = lblfznjujy abepnermtd (ygwewcxzbu )
Phase 1/2
49
(psddpagsoq) = netckioyds guytutnugv (zithqmymjr )
Positive
22 Apr 2024
Phase 2
35
(gyifqpmuqk) = gmukdoytjn owglzxnicb (wxjflbjaxp, 4.8 - 30.3)
Negative
05 Apr 2024
Phase 3
-
(drbvuflpoh) = ntpdujxzmt jeiwctkbnm (qwjlobbfqx, 7.4 - 10.9)
Positive
06 Dec 2023
(drbvuflpoh) = cvnxwdjysl jeiwctkbnm (qwjlobbfqx, 5.6 - 8.1)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free